Journal of Proteomics & Bioinformatics
Open Access

Artificial Intelligence in Drug Discovery Accelerating Therapeutic Development

Emily Johnson^{* *}Correspondence: Emily Johnson, Department of Molecular Informatics and AI Systems Faculty of Life Sciences and Technology, University Boston, Massachusetts, USA, Email:

Author info »

Description

Drug discovery has undergone a profound transformation over the past few decades, shifting from largely serendipitous identification of bioactive compounds to a highly structured, data-driven, and computationally enhanced scientific discipline. Traditionally, the process of identifying new therapeutic agents relied heavily on trial-and-error screening of natural products or synthetic chemical libraries, often requiring years of laboratory experimentation before a candidate emerged. While this empirical approach yielded several important drugs in the past, it was inefficient, expensive, and associated with a high failure rate during later stages of clinical development. Advances in molecular biology, structural chemistry, computational modeling, and high-throughput screening technologies have collectively reshaped the landscape, making drug discovery more rational, targeted, and efficient. At the core of modern drug discovery is the understanding of disease mechanisms at the molecular level. Diseases such as cancer, neurodegenerative disorders, and infectious diseases are now studied in terms of genetic mutations, protein dysfunctions, and complex biochemical pathways rather than just physiological symptoms. This mechanistic insight allows researchers to identify specific biological, typically proteins or nucleic acids, that play a crucial role in disease progression. These molecules, known as ligands or drug candidates, must bind with high specificity and affinity to their maintaining acceptable safety and pharmacokinetic properties. One of the most significant advancements in drug discovery has been the integration of computational approaches. In silico methods, including molecular docking, virtual screening, and quantitative structure-activity relationship modeling, have greatly accelerated the early phases of drug development. These techniques allow researchers to simulate the interaction between potential drug molecules and reducing the need for extensive laboratory testing. By screening millions of compounds virtually, scientists can prioritize a small subset of candidates for experimental validation, significantly reducing both time and cost. The increasing availability of structural data for proteins, especially through techniques such as X-ray crystallography and cryo-electron microscopy, has further enhanced the accuracy of these computational models. Artificial intelligence and machine learning have emerged as particularly powerful tools in this field. These methods can analyze vast datasets of chemical compounds, biological interactions, and clinical outcomes to identify hidden patterns that would be difficult for humans to detect. Machine learning models can predict drug-likeness, toxicity, solubility, and binding affinity with increasing accuracy, helping to filter out unsuitable compounds early in the pipeline. Deep learning approaches, especially those based on neural networks, have been used to generate novel molecular structures with desired properties, effectively enabling de novo drug design. This represents a shift from merely searching existing chemical space to actively exploring and creating new regions of it. Another major development is the application of high-throughput screening technologies. These systems are often combined with robotic handling and advanced imaging techniques to assess the effects of compounds on cellular models. While high-throughput screening provides valuable experimental data, it is often complemented by computational pre-screening to reduce the number of compounds that need to be physically tested. This synergy between computation and experimentation has become a hallmark of modern pharmaceutical research. The cost of drug development also remains a significant concern. Bringing a new drug to market can take over a decade and cost billions of dollars. Although computational methods and automation have reduced some of these burdens, regulatory requirements, clinical testing, and manufacturing challenges still contribute to high expenses. Efforts are being made to streamline regulatory pathways and improve collaboration between academia, industry, and regulatory agencies to make the process more efficient without compromising safety. In addition to small molecule drugs, biologics such as monoclonal antibodies, peptides, and gene therapies have gained prominence. These therapeutic modalities offer high specificity and disease mechanisms that are difficult to address with traditional small molecules. However, they also present unique related to stability, delivery, and production. Advances in protein engineering and delivery systems, including nanoparticle-based carriers and viral vectors, are helping to overcome some of these limitations. The drug discovery is likely to be increasingly interdisciplinary, combining insights from biology, chemistry, physics, computer science, and engineering. The rise of integrated platforms that combine genomic data, structural biology, and artificial intelligence is expected to further accelerate the identification of new therapeutic candidates. Moreover, the growing emphasis on open science and data sharing is enabling researchers worldwide to collaborate more effectively, reducing duplication of effort and fostering innovation.

References

1. Gribkoff VK, Kaczmarek LK. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology. 2017;120:11-19.

   [Crossref] [Google Scholar] [PubMed]

2. Zeng X, Tu X, Liu Y, Fu X, Su Y. Toward better drug discovery with knowledge graph. Curr Opin Struct Biol. 2022;72:114-126.

   [Crossref] [Google Scholar] [PubMed]

3. Cao D, Zhang P, Wang S. Advances in structure-based drug design: The potential for precision therapeutics in psychiatric disorders. Neuron. 2024;112(4):526-538.

   [Crossref] [Google Scholar] [PubMed]

4. Ozturk H, Ozgur A, Schwaller P, Laino T, Ozkirimli E. Exploring chemical space using natural language processing methodologies for drug discovery. Drug Discov Today. 2020;25(4):689-705.

   [Crossref] [Google Scholar] [PubMed]

5. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci. 2019;40(8):577-591.

   [Crossref] [Google Scholar] [PubMed]

6. Chen Y, Yang M, Hua Q. Artificial intelligence in central-peripheral interaction organ crosstalk: The future of drug discovery and clinical trials. Pharmacol Res. 2025;215:107734.

   [Crossref] [Google Scholar] [PubMed]

7. Jia S, Lai H, Bai H, Li M, Zhang Q, Zhao P, et al. Harnessing the application of artificial intelligence in identification of traditional Chinese medicines. J Ethnopharmacol. 2025:120704.

   [Crossref] [Google Scholar] [PubMed]

8. Reichel A. Addressing central nervous system (CNS) penetration in drug discovery: Basics and implications of the evolving new concept. Chem Biodivers. 2009;6(11):2030-2049.

   [Crossref] [Google Scholar] [PubMed]

9. Ali S, Tian X, Chen H, Zhou J. A New Era of Artificial Intelligence (AI): Transforming Drug Discovery and Development. J Med Chem. 2025;68(22):23643-23652. 

   [Crossref] [Google Scholar] [PubMed]

10. Zhang O, Lin H, Zhang X, Wang X, Wu Z, Ye Q, et al. Graph neural networks in modern AI-aided drug discovery. Chem Rev. 2025;125(20):10001-10003.

    [Crossref] [Google Scholar] [PubMed]